Hiromu Yano
Has grant
Assistant Professor (Tenure-track)
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Hiromu Yano is an Assistant Professor (Tenure-track) at Kumamoto University in Japan. His research primarily focuses on the interplay between immune microenvironments and cancer, particularly in the context of lung adenocarcinoma and glioblastoma. Recent articles highlight his work on immune cell profiles, the effects of aging on macrophage activity, and the implications of PD-1 therapy in various malignancies.
Recent Grants
Grant: Open
Deciphering Immune Evasion Mechanisms and Exploring Immunoactivating Strategies in Non-Tuberculous Mycobacterial Disease
Open Date: 2026-01-01
Close Date: 2026-12-01
Grant: Close
Application of semiconductor-based cell-shaping technology to establish in vitro tumor models and elucidate pathology
Open Date: 2024-01-01
Close Date: 2026-01-01
Grant: Close
Development of Novel Therapeutic Strategies for Nontuberculous Mycobacteriosis Targeting Host Cells
Open Date: 2024-01-01
Close Date: 2024-01-01
Grant: Open
Lipid metabolism as a novel prognostic factor and therapeutic target in multiple myeloma
Open Date: 2023-01-01
Close Date: 2027-01-01
Grant: Close
Therapeutic strategies targeting lipid metabolism in clear cell renal cell carcinoma
Open Date: 2023-01-01
Close Date: 2026-01-01
Articles (16)
Year:
2026
Year:
2026
Year:
2026
Non-tuberculous mycobacteria (NTM) infections are difficult to cure completely with current treatments, and no specific drugs are available. However, recent reports have indicated that immune checkpoint inhibitors may effectively treat pulmonary NTM infections. In this study, we investigated the expression of immune checkpoint molecules in macrophages, the host cells of NTM, and assessed their impact on the microenvironment of infected lesions. Bulk-RNA sequencing and western blot analyses revealed that macrophages infected with Mycobacterium avium , an NTM species, exhibited a pro-inflammatory phenotype and increased PD-L1 expression. Additionally, immunostaining of an NTM-infected mouse model and human tissues showed that increased PD-L1 expression in macrophages was associated with decreased T cell infiltration and increased T cell exhaustion (upregulated PD-1 expression) within infected lesions. These findings suggest that NTM infections evade cellular immunity by enhancing PD-L1 expression in macrophages. Therefore, PD-L1 inhibition may be a promising therapeutic strategy against NTM infections.
Year:
2026
Thyroid transcription factor-1 (TTF-1) is a lineage-specific marker for lung adenocarcinoma (LUAD), whereas the relatively minor subset of TTF-1-negative LUADs shows a poor prognosis and a limited response to therapy. However, its relationship with the tumor immune microenvironment remains poorly defined. How TTF-1 expression affects the immune context in LUAD was investigated, focusing on tumor-associated macrophages (TAMs) and T-cell infiltration. Immunohistochemical (IHC) analysis of 226 LUAD specimens showed that TTF-1-negative tumors were associated with epidermal growth factor receptor wild-type status, advanced stage, and worse progression-free and cancer-specific survivals. Notably, PD-L1 (programmed death-ligand 1) and PD-L2 expression in TAMs, but not in cancer cells, was significantly reduced in TTF-1-negative tumors. Public single-cell RNA sequencing data confirmed downregulation of CD274 (PD-L1) in TAMs from tumors with low expression of TTF-1-related genes. In contrast, PDCD1LG2 (PD-L2) expression showed less consistent patterns. On IHC analysis, infiltration of CD8 + and CD4 + T cells was modestly lower in TTF-1-negative tumors, accompanied by decreased HLA class I and II expressions. Transcriptomic analysis of The Cancer Genome Atlas LUAD cohort further showed lower interferon gamma (IFN-γ) signaling and decreased T cell-inflamed gene signatures in the low TTF-1-negative tumors. These findings suggest that TTF-1-negative LUAD exhibits more immune-suppressive features, with a relatively reduced antitumor immune response characterized by decreased T-cell infiltration and INF-γ signaling, which are related to PD-L1 and PD-L2 expressions in TAMs.
Year:
2025
Year:
2025
Glioblastoma (GBM) involves disruptions in the blood–brain barrier (BBB) and alterations in the immune microenvironment, including the activation of glioma‐associated macrophages (GAMs). Vascular endothelial growth factor inhibitors, commonly used in recurrent GBM treatment, can influence these processes. This study investigates the relationship between BBB disruption and GAM activation, focusing on plasmalemma vesicle‐associated protein (PLVAP), a marker of BBB disruption, and α1‐acid glycoprotein (AGP), an inflammatory protein implicated in tumor progression. PLVAP expression was analyzed by immunohistochemistry (IHC) in human GBM samples to determine correlations with tumor grade, proliferation, and GAM activation. Pre‐ and post‐bevacizumab treatment GBM samples were compared to assess changes in BBB integrity and macrophage activity. AGP's role in GAM activation was studied through in vitro assays and glioma implantation in AGP knockout mice, with assessments of tumor growth and angiogenesis. Results showed elevated PLVAP expression in higher‐grade gliomas, correlating with increased tumor proliferation and GAM activation, particularly around PLVAP‐positive vessels. Bevacizumab treatment reduced PLVAP expression and macrophage activity. AGP localized to regions of BBB disruption, promoting macrophage‐mediated tumor growth in vitro. AGP knockout mice demonstrated reduced angiogenesis and prolonged survival. Spatial analysis revealed increased expression of macrophage‐inducing molecules near PLVAP‐positive vessels. These findings suggest PLVAP as a marker of BBB disruption and glioma malignancy. AGP, associated with BBB leakage, contributes to GAM activation and tumor progression, highlighting its potential as a therapeutic target for GBM.
Year:
2025
The number of patients with prostate cancer has been increasing around the world. Although anticancer immunotherapy targeting the immune checkpoint molecules has been approved for many types of cancer, no significant anti-cancer effects have been observed in patients with prostate cancer. Lymph node sinus macrophages (LSMs) are known to work as antigen-presenting cells, which are critical for anticancer immune responses. Previous studies have suggested that CD169 expression in LSMs affects anticancer immune responses in several cancers, including prostate cancer. In the present study, we aimed to examine the correlation between the tumor immune microenvironment and activation status of LSMs in patients with prostate cancer. Forty-two cases of high-risk localized prostate cancer treated using robot-assisted laparoscopic radical prostatectomy and lymph node dissection between 2017 and 2021 were enrolled. CD169 expression in LSMs was examined by immunohistochemistry. The results indicated that CD169 expression in LSMs was significantly decreased in older (≥ 75 years) compared with younger patients. However, no significant correlation was found between CD169 expression and any other clinicopathological factors. In addition, CD3- and CD8-postitive lymphocytes in primary cancer tissues were evaluated in the same cases, and their correlations with CD169 expression in LSMs were tested. Although these lymphocytes tended to be higher in CD169 high than in CD169 low cases, the difference was not statistically significant. In conclusion, we found that CD169 expression was upregulated in older patients and tended to be related to T cell infiltration in cancer tissues. Therefore, the downregulation of CD169 in LSMs might be involved in the reduced anticancer immune response in prostate cancer.
Year:
2025
Oral squamous cell carcinoma (OSCC) is one of the most common head and neck cancers, and immunotherapy targeting programmed cell death 1 (PD‐1) has become a treatment option for recurrent OSCC after surgery and radiation therapy. However, few studies have identified definitive biomarkers for predicting patient response to anti‐PD1 therapy in OSCC. In the present study, biopsy specimens were obtained from 23 patients with recurrent OSCC who were subsequently treated with anti‐PD1 therapy. Immunohistochemical examinations of CD3, CD8, FOXP3, CD103, CD163, programmed cell death ligand 1 (PD‐L1), HLA‐A/B/C, HLA‐DR, and β2 microglobulin were performed, and their correlation with clinical response was statistically analyzed. We found that an increased density of CD8‐positive lymphocytes and increased PD‐L1 expression predicted a favorable response to anti‐PD1 therapy in recurrent OSCC. In contrast, clinical factors such as age and sex, and immune‐related factors such as HLA‐Classes I and II, were not associated with the response to anti‐PD1 therapy. Taken together, our results suggest that immunohistochemical analysis of CD8 and PD‐L1 may be useful for predicting the efficacy of anti‐PD1 therapy in recurrent OSCC.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Collaborators (8)
Yawara Kawano
Assistant Professor
Kumamoto University Hospital
hironori yoshida
Kyoto University Hospital
Toshihide Tanaka
Jikei University School of Medicine
Hiroaki Ozasa
助教 / Assistant Professor
Kyoto University
Rin Yamada
Kumamoto University Hospital
Noriko Yasuda
Kyushu University
Hiroshi Watanabe
Professor
Kumamoto University
Toru Takeo
Professor
Kumamoto University
Make your next move.
Prepare your application
Review drafts before you send them.